Literature DB >> 14636042

T cell immunity to brucellosis.

S Yingst1, D L Hoover.   

Abstract

Brucellosis is an ancient disease of animals and man that still threatens the health and prosperity of many, primarily in the third world, who depend on animal agriculture for their livelihood. Further, its pathogenicity and the facts that it is zoonotic is effectively eradicated from many Western nations make it a dangerous bioterrorism threat. Targeted human vaccination may reduce the various threats brucellosis poses. Significant effort has been expended toward this goal and many candidate vaccines exist. However, the ideal vaccine would be a subunit vaccine that specifically targets only the critical aspects of the immune response necessary to induce immunity. Much about the immune response, in particular the T cell response, remains to be discovered in order to accomplish that goal. In this review we focus on T cell responses to brucellosis with particular attention to the specific roles of T cell subtypes. We also point out areas of research on T cell responses that may allow exploitation of cutting edge vaccine technologies for the next generation vaccine for brucellosis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14636042     DOI: 10.1080/713608012

Source DB:  PubMed          Journal:  Crit Rev Microbiol        ISSN: 1040-841X            Impact factor:   7.624


  19 in total

1.  Hepatic and splenic immune response during acute vs. chronic Brucella melitensis infection using in situ microscopy.

Authors:  Juliane Daggett; Alexandra Rogers; Jerome Harms; Gary A Splitter; Marina Durward-Diioia
Journal:  Comp Immunol Microbiol Infect Dis       Date:  2020-10-02       Impact factor: 2.268

2.  Protective properties of rifampin-resistant rough mutants of Brucella melitensis.

Authors:  R Adone; F Ciuchini; C Marianelli; M Tarantino; C Pistoia; G Marcon; P Petrucci; M Francia; G Riccardi; P Pasquali
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

3.  Invasive Escherichia coli vaccines expressing Brucella melitensis outer membrane proteins 31 or 16 or periplasmic protein BP26 confer protection in mice challenged with B. melitensis.

Authors:  V K Gupta; G Radhakrishnan; J Harms; G Splitter
Journal:  Vaccine       Date:  2012-04-28       Impact factor: 3.641

4.  Immunization of mice with gamma-irradiated Brucella neotomae and its recombinant strains induces protection against virulent B. abortus, B. melitensis, and B. suis challenge.

Authors:  Dina Moustafa; Virendra K Garg; Neeta Jain; Nammalwar Sriranganathan; Ramesh Vemulapalli
Journal:  Vaccine       Date:  2010-11-23       Impact factor: 3.641

5.  CD80/CD28 co-stimulation in human brucellosis.

Authors:  P Skendros; P Boura; F Kamaria; M Raptopoulou-Gigi
Journal:  Clin Exp Immunol       Date:  2006-12       Impact factor: 4.330

6.  Discordant Brucella melitensis antigens yield cognate CD8+ T cells in vivo.

Authors:  Marina A Durward; Jerome Harms; Diogo M Magnani; Linda Eskra; Gary A Splitter
Journal:  Infect Immun       Date:  2009-11-02       Impact factor: 3.441

7.  Nondividing but metabolically active gamma-irradiated Brucella melitensis is protective against virulent B. melitensis challenge in mice.

Authors:  D M Magnani; J S Harms; M A Durward; G A Splitter
Journal:  Infect Immun       Date:  2009-08-24       Impact factor: 3.441

8.  Evaluation of recombinant invasive, non-pathogenic Eschericia coli as a vaccine vector against the intracellular pathogen, Brucella.

Authors:  Jerome S Harms; Marina A Durward; Diogo M Magnani; Gary A Splitter
Journal:  J Immune Based Ther Vaccines       Date:  2009-01-06

9.  Antigen-specific acquired immunity in human brucellosis: implications for diagnosis, prognosis, and vaccine development.

Authors:  Anthony P Cannella; Renee M Tsolis; Li Liang; Philip L Felgner; Mayuko Saito; Alessandro Sette; Eduardo Gotuzzo; Joseph M Vinetz
Journal:  Front Cell Infect Microbiol       Date:  2012-02-01       Impact factor: 5.293

10.  Immunogenic and invasive properties of Brucella melitensis 16M outer membrane protein vaccine candidates identified via a reverse vaccinology approach.

Authors:  Gabriel Gomez; Jianwu Pei; Waithaka Mwangi; L Garry Adams; Allison Rice-Ficht; Thomas A Ficht
Journal:  PLoS One       Date:  2013-03-22       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.